Literature DB >> 17425391

Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry.

Christopher L Owens1, Jonathan I Epstein, George J Netto.   

Abstract

CONTEXT: Poorly differentiated carcinoma on prostate or colorectal biopsy can occasionally present a diagnostic challenge in determining tumor source especially in locally advanced colorectal carcinoma (CRCa) or prostate carcinoma (PCa). Such determination can affect prognosis and therapy.
OBJECTIVE: To evaluate the role of morphology and immunohistochemistry in the previously mentioned setting.
DESIGN: Surgical pathology and consultation records. Hematoxylin-eosin sections were reviewed in 16 cases (11 PCa, 5 CRCa). Immunohistochemistry for 9 markers was performed in 15 cases.
RESULTS: Dirty necrosis, seen in 5 (100%) of 5 CRCa and 2 (18%) of 11 PCa cases, and the presence of columnar cells with basal nuclei, seen in 5 (100%) of 5 CRCa and 1 (9%) of 11 PCa cases, appear to be the most useful morphologic parameters. Immunohistochemistry confirmed the value of prostate-specific antigen (PSA), CDX2, cytokeratin (CK) 20, and beta-catenin in the differential of CRCa (0% PSA+, 60% CDX2+, 80% CK20+, and 100% beta-catenin+) versus PCa (80% PSA+, 0% CDX2+, 10% CK20+, and 0% beta-catenin+). P501S had a similar sensitivity as PSA in detecting PCa (80%). Two (20%) of 10 PCa cases were positive for 1 of the 2 markers but not the other. P501S was negative in all 5 cases of CRCa.
CONCLUSIONS: P501S is a useful marker in this setting when included together with PSA, CDX2, CK20, and beta-catenin. P501S labels a subset of PCa cases that are negative for PSA. Dirty necrosis and/or columnar cells with basal nuclei could also be of help.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425391     DOI: 10.5858/2007-131-599-DPFCAO

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

Review 1.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

2.  Expression of CDX2 in metastatic prostate cancer.

Authors:  C Guerrieri; Z Jobbagy; R Hudacko
Journal:  Pathologica       Date:  2019-09

3.  Metastasis of a cecal adenocarcinoma to the prostate five years after a right hemicolectomy: a case report.

Authors:  Fady R Youssef; Leanne Hunt; Pieter D Meiring; Danesh R Taraporewalla; Robin Gupta; Mike J James
Journal:  J Med Case Rep       Date:  2011-06-21

4.  Review of small cell carcinomas of the prostate.

Authors:  P Furtado; M V A Lima; C Nogueira; M Franco; F Tavora
Journal:  Prostate Cancer       Date:  2011-08-04

5.  Metastatic Prostate Cancer Presenting as a Rectal Polyp: A Rare Occurrence.

Authors:  Ese Uwagbale; Ifeanyichukwu Onukogu; Vimal Bodiwala; Solomon Agbroko; Niket Sonpal
Journal:  Cureus       Date:  2021-05-19

6.  Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.

Authors:  Ming Yin; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2007-10-27       Impact factor: 2.644

7.  Factors associated with the survival of prostate cancer patients with rectal involvement.

Authors:  Haitao Wang; Yanhong Yao; Baoguo Li
Journal:  Diagn Pathol       Date:  2014-02-20       Impact factor: 2.644

8.  Efficacy of Immunohistochemical Staining in Differentiating a Squamous Cell Carcinoma in Poorly Differentiated Rectal Cancer: Two Case Reports.

Authors:  Sairafi Rami; Yoon Dae Han; Mi Jang; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim
Journal:  Ann Coloproctol       Date:  2016-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.